Felipe Samaniego, M.D.

Peer-Reviewed Articles

1. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk ET, Hwang JP. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2020. PMID: 32314052.
2. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32628087.
3. Furqan F, Watson G, Samaniego F, Fayad LE, Rashmi Kanagal-Shamanna , Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32650677.
4. Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA. Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus-infected patients. Hematol Oncol 38(3):301-308, 2020. e-Pub 2020. PMID: 32196714.
5. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105(1):1907-1913, 2020. e-Pub 2019. PMID: 31601688.
6. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
7. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma 61(2):1-9, 2020. e-Pub 2019. PMID: 31533521.
8. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma 60(10):2432-2440, 2019. e-Pub 2019. PMID: 30942648.
9. Andraos T, Ayoub Z, Nastoupil L, Pinnix C, Milgrom S, Gunther J, Ng SP, Fowler N, Neelapu S, Samaniego F, Dabaja B. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clin Lymphoma Myeloma Leuk 19(6):381-389, 2019. e-Pub 2019. PMID: 30935940.
10. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma 60(13):1-8. e-Pub 2019. PMID: 31234671.
11. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882. e-Pub 2019. PMID: 30919940.
12. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6). e-Pub 2019. PMID: 30785215.
13. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol 185(4):670-678. e-Pub 2019. PMID: 30820940.
14. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. e-Pub 2018. PMID: 29723393.
15. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 103(9). e-Pub 2018. PMID: 29785709.
16. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103. e-Pub 2018. PMID: 29622656.
17. Hosry J, Miranda RN, Samaniego F, Economides MP, Torres HA. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142(5):940-948, 2018. e-Pub 2017. PMID: 29047108.
18. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28792260.
19. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
20. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthal Plast Reconstr Surg 33(5):355-360, 2017. e-Pub 2016. PMID: 27636243.
21. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin 67(5):411-431, 2017. e-Pub 2017. PMID: 28683174.
22. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood 130(4):472-477, 2017. e-Pub 2017. PMID: 28522441.
23. Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, Singh RK, Berkova Z, Wise JF, Braun FK, Wang X, Patel K, Xu-Monette ZY, Courty J, Young KH, Sehgal L, Samaniego F. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 32. e-Pub 2017. PMID: 28690315.
24. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
25. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
26. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
27. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2016. PMID: 27983760.
28. Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica 102(2):373-380, 2017. e-Pub 2016. PMID: 27742770.
29. Economides MP, Mahale P, Turturro F, Hosry J, Samaniego F, Granwehr BP, Torres HA. Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. Leuk Lymphoma 58(2):485-488, 2017. e-Pub 2016. PMID: 27348218.
30. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100-111, 2017. e-Pub 2016. PMID: 27923552.
31. Takahashi K, Wang F, Kantarjian HM, Denaha D, Khann KK, Patel KP, Neelapu SS, Gumbs C, Bueso-Ramos CE, DiNardo CD, Colla S, Ravandi F, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futreal A. Clonal hematopoiesis increases the risk of therapy-related neoplasms. Blood 128(22):38, 2016.
32. Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med 14(1):346, 2016. e-Pub 2016. PMID: 27998273.
33. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
34. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
35. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 2016. PMID: 27227654.
36. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 2016. e-Pub 2016. PMID: 27091808.
37. Khashab T, Loghavi S, Konoplev SN, Samaniego F. Resolution of lung adenocarcinoma after discontinuation of ibrutinib. BMJ Case Rep 2016, 2016. e-Pub 2016. PMID: 27435843.
38. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
39. Moore JA, Moore MB, Samaniego F, Pinnix CC, Moore DF. Small lymphocytic lymphoma presenting with hypopituitarism. Am J Med 129(1):e9-e10, 2016. e-Pub 2015. PMID: 26344628.
40. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016. e-Pub 2015. PMID: 26640039.
41. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2015. PMID: 26648336.
42. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol 135(11):2775-84, 2015. e-Pub 2015. PMID: 26039541.
43. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
44. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 2015. e-Pub 2015. PMID: 26250576.
45. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 2015. e-Pub 2015. PMID: 26213141.
46. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
47. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272-4, 2015. e-Pub 2015. PMID: 25820332.
48. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
49. Zhu H, Berkova Z, Mathur R, Sehgal L, Khashab T, Tao RH, Ao X, Feng L, Sabichi AL, Blechacz B, Rashid A, Samaniego F. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res 13(5):809-18, 2015. e-Pub 2015. PMID: 25678597.
50. Berkova Z, Wang S, Sehgal L, Patel KP, Prakash O, Samaniego F. Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice. Histol Histopathol 30(5):559-68, 2015. e-Pub 2014. PMID: 25301266.
51. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. PEGylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients with Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2014. PMID: 25445468.
52. Braun FK, Mathur R, Sehgal L, Wilkie-Grantham R, Chandra J, Berkova Z, Samaniego F. Inhibition of Methyltransferases Accelerates Degradation of cFLIP and Sensitizes B-Cell Lymphoma Cells to TRAIL-Induced Apoptosis. PLoS One 10(3):e0117994, 2015. e-Pub 2015. PMID: 25738497.
53. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguera J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 2015. PMID: 26048374.
54. Khashab T, Sehgal L, Medeiros LJ, Samaniego F. Spontaneous regression of interdigitating dendritic sarcoma in a patient with concurrent small lymphocytic lymphoma. BMJ Case Rep 2015, 2015. e-Pub 2015. PMID: 26071439.
55. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 2014. e-Pub 2014. PMID: 25039868.
56. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6). e-Pub 2014. PMID: 24943107.
57. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical Value of Magnetic Resonance Imaging and Other Baseline Testing for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Leuk Lymphoma 55(5):1013-7, 2014. e-Pub 2013. PMID: 23879202.
58. Sehgal L, Mukhopadhyay A, Rajan A, Khapare N, Sawant M, Vishal SS, Bhatt K, Ambatipudi S, Antao N, Alam H, Gurjar M, Basu S, Mathur R, Borde L, Hosing AS, Vaidya MM, Thorat R, Samaniego F, Kolthur-Seetharam U, Dalal SN. 14-3-3γ meditated transport of plakoglobin to the cell border is required for the initiation of desmosome assembly in vitro and in vivo. J Cell Sci 127(Pt 10):2174-88, 2014. e-Pub 2014. PMID: 24610948.
59. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
60. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2013. PMID: 24332512.
61. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 28:2376–2387, 2014. e-Pub 2014. PMID: 24811343.
62. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631-8, 2013. e-Pub 2013. PMID: 23802738.
63. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2), 2013. e-Pub 2012. PMID: 23276888.
64. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 121(23):4729-39. e-Pub 2013. PMID: 23599269.
65. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1), 2013. e-Pub 2012. PMID: 23137719.
66. Oellers P, Savar A, Samaniego F, Pro B, Esmaeli B. Second-Line 90Yttrium-Ibritumomab Tiuxetan (Zevalin) in a Patient With Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma Refractory to Rituximab. Ophthal Plast Reconstr Surg 28(6):e145-6, 2012. PMID: 22820440.
67. Daniluk U, Kerros C, Tao RH, Wise JF, Ao X, Berkova Z, Samaniego F. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematopoietic cancer cells. J Exp Clin Cancer Res 31(1):69, 2012. e-Pub 2012. PMID: 22929310.
68. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 2012. e-Pub 2012. PMID: 22677155.
69. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(18), 2012. e-Pub 2012. PMID: 22586182.
70. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2011. PMID: 22015451.
71. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 2012. e-Pub 2012. PMID: 22023528.
72. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Shabib Dabaja B, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-4128, 2012. e-Pub 2012. PMID: 22371887.
73. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 118(4):1023-31, 2012. e-Pub 2011. PMID: 21761401.
74. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30(49):4874-86, 2011. e-Pub 2011. PMID: 21625222.
75. Wang J, Han F, Wu J, Lee SW, Chan CH, Wu CY, Yang WL, Gao Y, Zhang X, Jeong YS, Moten A, Samaniego F, Huang P, Liu Q, Zeng YX, Lin HK. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood 118(20):5429-38, 2011. e-Pub 2011. PMID: 21931116.
76. Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, Hawke DH, Karp JE, Lin HK, Molldrem JJ, Samaniego F. PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood 118(11):3107-18, 2011. e-Pub 2011. PMID: 21803845.
77. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 2011. e-Pub 2011. PMID: 21517809.
78. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 2010. e-Pub 2010. PMID: 20528872.
79. Ho HH, Savar A, Samaniego F, Manning J, Kasyan A, Pro B, Esmaeli B. Treatment of benign lymphoid hyperplasia of the orbit with rituximab. Ophthal Plast Reconstr Surg 26(1):11-3, 2010. PMID: 20090476.
80. Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs 19(1):141-9, 2010. PMID: 19968579.
81. Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2. Structure, function, and post-translational regulation. J Biol Chem 269(49):30904-10, 1994. PMID: 7983023.

Invited Articles

1. Samaniego FS, Matias KP.. Studies of the Viral Origins of Some Cancers Lead to New Prevention Treatment Strategies, 2004.
2. Pati S, Lee Y, Samaniego F. Urinary proteins with pro-apoptotic and anti-tumor activity. Apoptosis 5(1):17-24, 2000. PMID: 11227487.

Manuals, Teaching Aids, Other Teaching Publications

1. Samaniego, F, Matias KP. Studies of the viral origins of some cancers lead to new prevention, treatment strategies, 2004.
2. Samaniego F. The viral origins of lymphomas, 2002.

Abstracts

1. Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA. Clinicopathologic Characteristics of Follicular Lymphoma in Hepatitis C Virus-Infected Patients(23), 2020.
2. Swami P. Iyer, MD , Sattva S Neelapu, MD , Ethan Burns, MD , Ranjit Nair, MBBS,MD , Chitra Hosing, MD , Yago Nieto, MD PhD , Jason R. Westin, MD , Simrit Parmar, MBBS , Nathan H. Fowler, MD , Loretta J. Nastoupil, MD MSc , Madeleine Duvic, MD , Roberto N. Miranda, MD , Hun Ju Lee , Felipe Samaniego, MD , Sairah Ahmed, MD , Feng Lei, MS , Auris Huen, MD. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Blood Journal 134(Suppl 1), 2019.
3. Chelsea C Pinnix, MD PhD , Jillian R Gunther, MD PhD , Bouthaina S. Dabaja, MD , Sherry Adkins, ANP , Misha Hawkins , Jason R. Westin, MD , Luis Fayad, MD , Sairah Ahmed, MD , Nathan H. Fowler, MD , Fredrick B. Hagemeister, MD , Swaminathan P. Iyer, MD , Maria Alma Rodriguez, MD , Hun Ju Lee , Raphael E Steiner, MD , Ranjit Nair, MBBS,MD , Paolo Strati, MD , Simrit Parmar, MBBS , Felipe Samaniego, MD , Michael Wang, MD , Sattva S Neelapu, MD , Loretta J. Nastoupil, MD MSc. Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Blood Journa 134(Suppl 1), 2019.
4. Loretta J. Nastoupil, MD MSc , Jason R. Westin, MD , Fredrick B. Hagemeister, MD , Hun Ju Lee , Luis Fayad, MD , Felipe Samaniego, MD , Sairah Ahmed, MD , Linda Claret , Raphael E Steiner, MD , Ranjit Nair, MBBS,MD , Simrit Parmar, MBBS , Maria Alma Rodriguez, MD , Michael L. Wang, MD , Michael R Green, PhD , Eric Davis, MD , Sattva S Neelapu, MD , Nathan H Fowler, MD. Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL). Blood Journal 134(Suppl 1), 2019.
5. Loretta J. Nastoupil, MD MSc , Sattva S Neelapu, MD , Eric Davis, MD , Felipe Samaniego, MD , Nathan H Fowler, MD , Jason R. Westin, MD , Hun Ju Lee , Michael Wang, MD , Fredrick B. Hagemeister, MD , Philip Beer, MD PhD , Alexander R. L. Cecil , James Dow , Duncan McHale , Franck Silva , Penny Ward , Arash Yavari , Stephen Joseph Shuttleworth, PhD. Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma. Blood Journal 134(Suppl 1), 2019.
6. Nastoupil L, Westin JR, Fowler NH, Fanale MA, Samaniego F, Oki Y, Dsouza L, Obi C, Cao J, Cheng X, Ma MCJ, Zhiqiang W, Feng L, Zhou S, Davis RE, Neelapu SS. High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study. Blood ASH 2017 130(Suppl 1):414, 2017.
7. Becnel MR, Nastoupil L, Davis RE, Hagemeister FB, Fanale MA, Fayad L, Westin JR, Wang M, Oki Y, Claret L, Forbes SG, Feng L, Samaniego F, Neelapu SS, Fowler N. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. Blood ASH 2017 130(Suppl 1):4040, 2017.
8. Hosry J, Miranda RN, Turturro F, Economides MP, Samaniego F, Torres HA. Clinicopathologic Characteristics and Outcomes of Transformed Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Infected Patients: A Case-Control Study of 84 Patients. J Clin Oncol 35(15), 2017.
9. Fowler N, Neelapu S, Samaniego F, Forbes S, Hagemeister FB, Fayad L, Feng L, Turturro F, Westin JR, Arafat J, Neal E, Nastoupil LJ. Activity of the Immunologic Doublet of Lenalidomide Plus Obinutuzumab in Relapsed Follicular Lymphoma: Results of a Phase I/II Study. J Clin Oncol 35(15), 2017.
10. Nastoupil LJ, Westin JR, Fowler N, Fanale MA, Samaniego F, Oki Y, Obi C, Cao J, Cheng X, Ma MCJ, Wang Z, Chu F, Feng L, Zhou S, Davis RE, Neelapu S. Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Interim Results of an Open-Label, Phase II Study. J Clin Oncol 25(15), 2017.
11. Khashab T, Niaz MO, Hagemeister FB, Romaguera JE, Fanale, MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu S, Fayad L, Younes A, Feng L, Berkova Z, Jain N, Sehgal L, Vega F, Kwak LW, Samaniego F. Ten-Year Follow-Up of Pentostatin Combined with Cyclophosphamide, and Rituximab in Previously Untreated Indolent B-Cell Lymphoma. J Cllin Oncol 35(15), 2017.
12. Hu B, Loghavi S, Fayad L, Noorani M, Fowler N, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu S, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in The Rituximab (R) Era. J Clin Oncol 35(15), 2017.
13. Wang M, Lee HJ, Thirumurthi S, Chauang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Li S, Zhang L, Badillo M, Hartig KH, Shmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Blood 128(22):147, 2016.
14. Bueso-Ramos E, DiNardo CD, Colla S, Ravandi F, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futreal A. Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. Blood 128(22):38, 2016.
15. Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood 128(22), 2016.
16. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu S, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood 128(22):1833, 2016.
17. Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler N. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III. Blood 128(22), 2016.
18. Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Shaoying l, Zhang L, Rodriguez MA. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Therapeutic Approaches to Mantle Cell Lymphoma. Blood 128(22), 2016.
19. Jason JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I. Blood 128(22), 2016. e-Pub 2016.
20. Hosry J, Samaniego F, Turturro F, Economides MP, Torres HA. Effect of Lenalidomide on Hepatitis C Viremia in Cancer Patients: A Case Series. Blood 128(22):5691, 2016.
21. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and ATL. Blood 126(23), 2015.
22. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23), 2015.
23. Chihara D, Oki YY, Westin JR, Nastoupil L, Fayad LE, Samaniego F, Wesson E, Ruben C, Horwoitz SB, Feng L, Carg N, Ahmed S, Khouri IF, Hosing Cm, Romaguera JE, Nathan F, Fanale M. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood 126(23), 2015.
24. Fanale MA, Wang Z, Ma W, Oki Y, Hagemeister FB, Fayad LE, Fowler N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto TY, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B-and T-Cell Lymphomas. Blood 126(23), 2015.
25. Fowler N, Pinto RM, Cheah CY, Neelapu SS, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Ant-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood 126(23), 2015.
26. Sehgal L, Tamer K, Wang X, Mathur R, Berkova Z, Romaguera JE, Rodriguez A, Neelapu SS, Samaniego F. Tumor Microenvironment Regulates Survival of Mantle Cell Lymphoma Cells through Various Signaling Pathways. Blood 126(23), 2015.
27. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23), 2015.
28. Mathur R, Sehgal L, Berkova Z, Neelapu S, Samaniego F.. Inhibition of demethylase, JMJD3 sensitizes diffuse large B-cell lymphoma (DLBCL) to chemotherapy. AACR Annual Meeting, 2015.
29. Sehgal L, Berkova Z, Khashab T, Wang X, Romaguera JE, Rodriguez AE, Neelapu S, Samaniego F. Tumor microenviornment influences survival of mantle cell lymphoma-initiating cells through FGF/FGFR1 signaling. AACR Annual Meeting, 2015.
30. Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin JR, Kwak LW. SUV on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood 124(21), 2014.
31. Oki Y, Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, and Fayad LE.. Double Hit Lymphoma: M.D. Anderson Experience. Blood 122(21), 2013.
32. Hagemeister FB, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, Cabanillas F.. Long Term Results of a Phase 2 Study of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood 122(21), 2013.
33. Thomas SK, Haygood TM, Qazilbash MH, Melendez AG, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM.. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122(21), 2013.
34. Samaniego F, Romaguera JE, Fowler Nathan, Fanale MA, Shah JJ, McLaughlin P, Pro B, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu S, Kwak LW.. A Single Center Phase II Trial of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease. Blood 122(21), 2013.
35. Berkova Z, Ao X, Braun FK, Wise JF, Sehgal L, Samaniego F.. CD74 Interferes With The Expression of Fas Receptor On The Cell Surface. Blood 122(21), 2013.
36. Braun FK, Mathur R, Sehgal L, Berkova Z, and Samaniego F.. Histone 3 Methyltransferase (EZH2) Inhibition Enhances TRAIL-Induced Apoptosis In Mantle Cell Lymphoma Cells By Accelerated cFLIP Degradation. Blood 122(21), 2013.
37. Samaniego F, Wise J, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel K, Neelapu SS, Kwak LW, Berkova Z.. Regulation of Fas-mediated Apoptosis by Nucleolin in B-cell Lymphomas. 12th International Conference on Malignant Lymphoma, 2013.
38. Samaniego F, Mathur R, Berkova Z, Braun FK.. Histone 3 methyltransferase (EZH2) inhibition results in accelerated caspase-8 processing and enhances TRAIL-induced apoptosis in mantle cell lymphoma cells. 12th International Conference on Malignant Lymphoma, 2013.
39. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W,Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, Peter McLaughlin PM, McDonnell TJ, Patel K, Neelapu SS, Kwak LW, Zuzana Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood 120(21), 2012.
40. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemeister FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JE, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood 120(21), 2012.
41. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood 120(21), 2012.
42. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood 120(21), 2012.
43. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad JE, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood 120(21), 2012.
44. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood 120(21), 2012.
45. Tao RH, Berkova Z, Wise JF, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Samaniego F. Mechanism of Regulating Fas Signaling by Promyelocytic Leukemia Protein (PML) and Its Dominant-Negative Mutant PMLRARα. Blood 120(21), 2012.
46. Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte LC, Samaniego F, Davis ER, Neelapu SS. Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. Blood 120(21), 2012.
47. Samaniego F, Berkova Z, Wise JF, Kerros C, Hawke DH, Karp JE, Lin H, Molldrem JJ, Tao R. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. Blood 118(21), 2011.
48. Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, PhD, David H Hawke, Judith E. Karp Hui-Kuan Lin, Jeffrey J. Molldrem and Rong-Hua Tao. PML and PMLRARα Interact with Fas to Regulate Fas-Mediated Apoptosis In Vivo. (ASH Meeting Abstract). Blood 118(21), 2011.
49. Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, David H Hawke, Judith E. Karp, Hui-Kuan Li, Jeffrey J. Molldrem, and Rong-Hua Tao. Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo. (ASH Meeting Abstract). Blood 118(21), 2011.
50. Perini GF, Romaguera MA, Rodriguez B, Pra A, Younes NH, Fowler FB, Hagemeister F, Samaniego F, Kwak LW, Fayad L. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. Clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. 2010 ASCO Annual Meeting Abstract, 2010.
51. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. 2010 ASCO Annual Meeting Abstract, 2010.
52. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). 2010 ASCO Annual Meeting Abstract, 2010.
53. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. 2010 ASCO Annual Meeting Abstract, 2010.
54. Andreef M, Kojima K, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, O'brien S, Samaniego F, Borthakur G, Konopleva M, Vassilev L, Nichols G.. A multi-center, open-label, phase I study of single agent RG7112, A first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lympyhocytic lymphomas (CLL/SCLL). Blood 116(21):287, 2010.
55. Fanale MA, Chao-Ming L, McLaughlin P, romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak L, Dong W, Reed V, Dabaja BS, Popat U, younes A. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood 116(21):1159, 2010.
56. Tao RH, Berkova Z, Wise J, Daniluk U, Bai L, Ao X, Samaniego F. Direct suppression of Fas-Mediated apoptosis by PMLRARa through forming an apoptotic inhibitory complex with c-FLIP in acute promyelocytic leukemia. Blood 116(21):1297, 2010.
57. Okoroji GJ, de Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): allografting vs. conventional therapy. Blood 116(21):1442, 2010.